Mpox Vaccine Hesitancy Among Brazilian Men Who Have Sex with Men: A National Cross-Sectional Study

巴西男男性行为者对麻疹疫苗的犹豫态度:一项全国横断面研究

阅读:2

Abstract

BACKGROUND: Mpox is a viral zoonosis that has gained increased attention due to a global outbreak in 2022, significantly impacting men who have sex with men (MSM). Vaccination for this disease poses a public health challenge; because it carries a strong stigma, there may be greater hesitancy in vulnerable groups. OBJECTIVES: This study aimed to determine the prevalence and factors associated with Mpox vaccine hesitancy among Brazilian MSM. METHODS: A cross-sectional study was conducted between September and December 2022 using an online survey targeted at MSM. Recruitment was carried out through social media and dating apps. The sample consisted of 1449 participants and the analysis involved bivariate logistic regression. RESULTS: The prevalence of Mpox vaccine hesitancy was 7.57%. The significant factors associated with hesitancy were primarily related to sexual practices and attitudes towards Mpox exposure and diagnosis, such as not using "glory holes" (aOR: 19.82; 95% CI: 1.60-245.69), reluctance to undergo pre- and post-exposure testing for Mpox (aOR: 9.54; 95% CI: 5.52-16.48), and not knowing close contacts diagnosed with Mpox (aOR: 4.09; 95% CI: 1.72-9.73). Participants who would not take precautions after diagnosis (aOR: 3.00; 95% CI: 1.27-7.07) and those who would not disclose their serological status (aOR: 1.93; 95% CI: 1.13-3.30) also showed a higher likelihood of vaccine hesitancy. CONCLUSION: Public health strategies should address these factors to expand knowledge about vaccination barriers, plan educational campaigns with targeted messaging for the MSM population, and provide inclusive healthcare environments to increase vaccine acceptance and reduce Mpox transmission in vulnerable groups.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。